Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection  by Tapia, Natalia et al.
www.elsevier.com/locate/yviroVirology 338 (Combination of a mutagenic agent with a reverse transcriptase
inhibitor results in systematic inhibition of HIV-1 infection
Natalia Tapiaa, Guerau Ferna`ndeza, Mariona Pareraa, Gemma Go´mez-Marianob,
Bonaventura Cloteta, Miguel Quin˜ones-Mateuc, Esteban Domingob, Miguel Angel Martı´neza,*
aFundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
bCentro de Biologı´a Molecular ‘‘Severo Ochoa’’, Consejo Superior de Investigaciones Cientı´ficas, Universidad Auto´noma de Madrid, Madrid, Spain
cDepartment of Molecular Biology, Section of Virology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Received 24 January 2005; returned to author for revision 29 March 2005; accepted 6 May 2005
Available online 6 June 2005Abstract
Mutagenic treatments resulted in occasional, not systematic, human immunodeficiency virus type 1 (HIV-1) extinction. To study the
possibility that a combination of an antiretroviral inhibitor, to reduce the viral replicative load, and a mutagenic agent could be more effective
in producing viral extinction than a mutagenic agent alone, we have compared the efficiency of extinction of HIV-1 by the mutagenic
deoxyribonucleoside analogue 5-hydroxydeoxycytidine (5-OHdC) alone and in combination with the HIV-1 nucleoside reverse transcriptase
(RT) inhibitor AZT. Serial passages in peripheral mononuclear cells (PBMC) or MT-4 cells of primary HIV-1 isolates or HIV-1 NL4-3 in the
presence of a single drug (AZT 0.01AM or 5-OHdC 2 mM) failed to systematically extinguish high fitness HIV-1 replication after 16 serial
transfers. However, systematic extinction of HIV-1 was observed when a combination of the mutagenic agent 5-OHdC and AZT was used.
These results demonstrate that combinations of mutagenic agents and antiretroviral inhibitors have the potential to drive HIV-1 into
extinction.
D 2005 Elsevier Inc. All rights reserved.Keywords: HIV-1; Antiretroviral therapy; Lethal mutagenesisIntroduction
Maintenance of genetic information of any organism
requires a minimal fidelity level during copying of template
molecules in the process of genome replication. In the case
of RNAviruses, an increase in the average error rate above a
critical threshold during viral replication should result in the
loss of genetic information in a process that has been
referred to as violation of the error threshold or entry into0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.05.008
Abbreviations: 5-OHdC, 5-hydroxydeoxycytidine; RT, reverse tran-
scriptase; PBMCs, peripheral mononuclear cells; FMDV, foot-and-mouth
disease virus; CC50, concentration needed to kill 50% of the cells; IC50,
50% inhibitory concentration; TCID50, tissue culture dose for 50%
infectivity; MOI, multiplicity of infection; PHA, phytohemagglutinin.
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2000; Domingo et al., 2005; Eigen, 2002). If RNA virus
quasispecies go beyond this mutational limit, the population
will no longer be viable. Theoretical and experimental
studies suggest that mutation rates for RNAviruses are close
to this error threshold and can be forced into error
catastrophe by a moderate increase in mutation rate (a
process called lethal mutagenesis) (Anderson et al., 2004;
Domingo, 2000; Domingo et al., 2005; Eigen, 2002; Smith
et al., 2005). Several studies have provided evidence of
drastic losses of viral infectivity employing mutagenic
ribonucleoside or deoxyribonucleoside analogues (Crotty
et al., 2000; Grande-Perez et al., 2002; Loeb et al., 1999;
Sierra et al., 2000). Specifically, mutagenic treatments
resulted in occasional, not systematic, HIV-1 extinction.
Loeb et al. (1999) found that a slight increase in mutation
frequency of HIV-1 resulted in a significant reduction in2005) 1 – 8
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presence of the mutagenic deoxyribonucleoside analogue
5-OHdC increased the mutation frequency by less than 2-
fold, but it was sufficient to produce a loss of replicative
potential of HIV-1 that led occasionally to viral extinction.
Efficient extinction of foot-and-mouth disease virus
(FMDV) and lymphocytic choriomeningitis virus was
documented by using 5-fluorouracil, or 5-azacytidine
(Grande-Perez et al., 2002; Sierra et al., 2000) or
combinations of mutagen and antiviral inhibitors (heparin
and guanidine hydrochloride) (Pariente et al., 2001, 2003),
without observing an increase in mutations conferring
resistance to the inhibitor. In addition, the ribonucleoside
analogue ribavirin has been recently associated with lethal
mutagenesis of poliovirus, hepatitis C virus, Hantaan virus
and FMDV (Airaksinen et al., 2003; Crotty et al., 2000; de
la Torre, 2005; Jonsson et al., 2005; Lanford et al., 2001;
Pariente et al., 2005; Severson et al., 2003; Vignuzzi et al.,
2005).
Therapeutic options against HIV-1 continue to expand
with the development of new drugs and new strategies for
using them. Nevertheless, the management of HIV-1-
infected patients has become increasingly complex (Vol-
berding, 2003). The emergence of drug-resistance and the
growing recognition of the long-term toxicity of antiretro-
viral agents justify a continued effort to develop new
antiviral strategies. The aim of the present report has been to
explore an antiviral strategy based on increasing the HIV-1
mutation rate above a threshold value beyond which the
viral population cannot be sustained because of a loss of
viral replication capacity and infectivity. Here, we compare
the effect of a mutagenic agent (5-OHdC), alone and in
combination with an antiretroviral inhibitor (AZT), on HIV-
1 replication. The effect of viral fitness on HIV-1 extinction
by 5-OHdC is also explored.Results
Systematic extinction of primary HIV-1 isolates in PBMCs
by a combination of 5-OHdC and AZT
Previous results showed that serial passage of HIV-1LAI
in CEM cells in the presence of 1 mM of 5-OHdC resulted
in occasional, not systematic, extinction of the virus
(Anderson et al., 2004; Loeb et al., 1999). We evaluated
the frequency of extinctions of two HIV-1 primary isolates,
F96 and F98, by serial passages in PBMCs in the presence
of 2 mM of 5-OHdC (Figs. 1A and B, respectively). We
analyzed two different HIV-1 isolates from the same patient
(i.e., wild type, F96 strain; and the posttherapy-multidrug
resistant, F98) to test the possible influence of HIV-1 fitness
in lethal mutagenesis. Fitness of the mutated F98 isolate was
4-fold lower than that of wt F96 (i.e., 25% and 96% relative
to the wild type NL4-3 virus used as control) (Weber et al.,
2003).In order to test whether mutagen plus antiretroviral
inhibitors could reduce virus production during serial
passages more than mutagenic treatment alone, the primary
HIV-1 isolates F96 and F98 were grown in the presence and
absence of 2 mM 5-OHdC [concentration needed to kill 50%
of the cells (CC50) > 2 mM, 50% inhibitory concentration
(IC50) > 2 mM)], alone or in combination with IC50
concentrations (0.01 AM) of AZT (Fig. 1). A more efficient
inhibition of HIV-1 production was observed during serial
passages in the presence of combinations of mutagenic agent
and AZT (Fig. 1). In all cases, viral extinction was obtained
after 5 serial transfers (5 weeks). In some serial transfers, it
was not possible to detect p24 antigen at passage 4 (Fig. 1).
Moreover, in those experiments in which at passage 4 the p24
antigen was detectable (10 to 100 pg/ml) (Fig. 1), proviral
DNAwas undetectable. This result suggests that 3 passages in
the presence of 5-OHdC and AZT were necessary to
extinguish the F96 an F98 isolates. As expected, passages
in the presence of a single drug (i.e., AZT) failed to extinguish
HIV-1 (Fig. 1). These results indicate that indeed a
combination of mutagenic analogues and antiretroviral
inhibitors can be more effective than a mutagenic analogue
alone in driving HIV-1 into extinction. Altogether, these
results suggest that a combination of mutagenic nucleoside
analogues with AZT may be used to lead both high fitness
and low fitness viruses into extinction.
No extinction of the high fitness isolate F96 in the presence
of 5-OHdC alone
Extinction of HIV-1 F96 or F98 in the presence of 5-
OHdC alone was not observed after 5 passages (5 weeks)
(Fig. 1). To test whether the F96 and F98 isolates could be
extinguished in PBMCs in the presence of 5-OHdC alone, as
it was previously observed with HIV-1LAI in CEM cells
(Loeb et al., 1999), a new series of sequential transfers were
performed (Fig. 2). In the two series in which the F98 isolate
was propagated in 5-OHdC-treated cultures, the p24 antigen
was undetectable after 10 passages. Interestingly, in the two
5-OHdC-treated cultures in which the F96 was propagated,
virus was detected during the 16 passages conducted (Fig. 2).
These results show the influence of viral fitness in determin-
ing virus extinction by an increase in mutation frequency.
Extinction of the HIV-1 NL4-3 in MT4 cells by a
combination of 5-OHdC and AZT
To further assess the antiviral effectiveness of the 5-
OHdC and AZT combination, we performed similar experi-
ments with the fast replicating HIV-1 strain NL4-3 in MT4
cells, in which the replication capabilities of the virus are
augmented. Using this system, it was possible to test higher
viral titers than using PBMCs as target cells (Figs. 2 and 3),
although now less amount of p24, 500 pg versus 6000 pg
(F96/F98), was transferred to fresh cells during the serial
passages. Again, systematic HIV-1 extinction was achieved
Fig. 1. Serial passages of HIV-1 F96 (A) and F98 (B) isolates in the absence or presence of 5-OHdC, AZT or the combination of 5-OHdC and AZT. Three
different experiments for each isolate are shown. HIV-1 isolates F96 or F98 were added at a MOI of 0.01 TCID50/cell to 1 ml of medium containing 7  105
PHA-stimulated, IL-2-treated PBMCs from HIV-seronegative blood donors. The origin of HIV-1 F96 and F98 and conditions for mutagenic and antiretroviral
treatment are described in Materials and methods.
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Fig. 3. Serial passages of HIV-1 NL4-3 in the absence or presence of 5-
OHdC, AZT or 5-OHdC-AZT. Three different experiments are shown.
Serial passages were performed by infecting 2  105 MT-4 cells with HIV-1
NL4-3 at the MOI of 0.01 TCID50/cell.
Fig. 2. Serial passages of HIV-1 F96 and F98 isolates in the absence or
presence of 5-OHdC. Two different experiments are shown. HIV-1 isolates
F96 or F98 were added at a MOI of 0.01 TCID50/cell to 1 ml of medium
containing 7  105 PHA-stimulated, IL-2-treated PBMCs from HIV-
seronegative blood donor.
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and AZT (3.5, 4 or 6 weeks of culture, respectively),
depending of the experiment (Fig. 3). Similarly, it was
possible to occasionally extinguish the virus when propa-
gated in the presence of the mutagenic agent alone (Fig. 3),
although at later passages. Viral extinction was not achieved
in any experiment when the virus was cultured with IC50
concentrations (0.01 AM) of AZT. Therefore, a fast
replication scenario and high viral titters do not prevent
the extinction of the virus in the presence of the 5-OHdC
and AZT combination.
5-OHdC-AZT induced mutations
The mutation frequency and mutant spectrum in 5-OHdC-
AZT-treated cultures and controls are shown in Table 1. The
mutation frequency in the controls and in the 5-OHdC-AZT-
treated cultures (passage 2, experiment 1 in Figs. 1A and B)
Table 1
Mutation frequency and types of mutations in the HIV-1 protease-coding region of infected cultures treated with 5-OHdC and AZT




% No. and mutation type
AYC AYG AYT CYA CYG CYT GYA GYC GYT TYA TYC TYG In/
dels
F96a Control 24 39/10968 0.35 1 14 1 2 0 3 10 0 0 2 4 0 1/1
5-OHdC-AZT 60 75/27420 0.27 0 22 5 0 0 7 18 1 0 3 18 0 0/4
F98b Control 64 121/27136 0.44 2 41 13 0 0 1 17 1 0 11 30 0 0/5
5-OHdC-AZT 62 117/26846 0.43 0 42 4 1 1 2 20 0 0 6 28 4 0/9
NL4-3p1c Control 34 32/15243 0.20 1 15 0 0 0 2 4 0 1 2 7 0 0/0
5-OHdC-AZT 35 61/16181 0.37 1 31 2 1 1 0 9 0 1 0 13 2 0/0
NL4-3p5d Control 36 62/16452 0.37 1 21 2 0 0 3 14 1 2 1 16 1 0/0
5-OHdC-AZT 37 46/16520 0.27 1 21 2 0 0 6 2 0 0 3 11 0 0/0
a Proviral DNA was amplified from experiment 1 passage 2 (Fig. 1A).
b Proviral DNA was amplified from experiment 1 passage 3 (Fig. 1B).
c Proviral DNA was amplified from experiment 2 passage 1 (Fig. 3).
d Proviral DNA was amplified from experiment 2 passage 5 (Fig. 3).
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0.44% and 0.43%, respectively for isolate F98. Similarly, the
mutation frequency observed in the control and 5-OHdC-
AZT-treated culture of the HIV-1 NL4-3 strain in MT-4 cells
(passage 5, experiment 2 in Fig. 3) was 0.37% and 0.27%,
respectively. These results show an absence of mutation
frequency increase in the preextinction 5-OHdC-AZT-
treated cultures. We next measured the mutation frequency
of passage 1 (experiment 2 in Fig. 3) of control and 5-OHdC-
AZT-treated culture of NL4-3 because it was the only
passage in the presence of 5-OHdC-AZT in which a
significant increase in the viral titer was observed. Although
this passage was not a preextinction population, it was
possible to detect an increase in the number of substitutions
in the 5-OHdC-AZT-treated culture, 0.20% and 0.37% for
control and 5-OHdC-AZT-treated culture, respectively, as
well as a 2-fold increase in the number of G to A and A to G
substitutions (Table 1). This finding suggests that the
bottleneck originated after the first passage in the presence
of 5-OHdC-AZT may have drastically reduced the hetero-
geneity of the former viral population.Discussion
Most evaluations of extinction of RNA viruses in the
presence of mutagens have been performed in the presence
of the mutagenic agent alone. Here, we show a more efficient
inhibition of HIV-1 replication when combinations of a
mutagenic agent and an antiretroviral inhibitor, AZT, were
used. The HIV-1 extinction was systematic in the presence of
mutagen and AZT, in contrast to the passages with mutagen
alone in which HIV-1 extinction was occasional (Fig. 1)
(Loeb et al., 1999). After 16 weeks of culture in the presence
of 5-OHdC, the replication of the high fitness F96 isolate
was never abolished (Fig. 2). As suggested previously
(Anderson et al., 2004; Loeb et al., 1999), escape from
lethal mutagenesis may result from persistence of the wild-
type virus. Our findings regarding the efficacy of the 5-OHdC and AZT combination are in agreement with the
current views on adaptability of viral quasispecies (Domi-
ngo, 2003; Domingo et al., 2005). Combination therapy with
two or more inhibitors will limit the chances of generating
and selecting inhibitor-resistant mutants (Ho, 1998). It is
also important to emphasize the potency of the combination
employed here. Only a few viral transfers, in the presence of
this combination, were sufficient to extinguish the virus.
Although a few picograms of p24 from isolates F96 and F98
were detectable at passage 4 (Fig. 1) proviral DNA was
undetectable at this stage, suggesting that only 3 passages in
the presence of 5-OHdC and AZT were sufficient to
extinguish F96 and F98. Furthermore, in most of the serial
viral transfer experiments performed, the inhibitory potency
of the combination used was observed after the first passage
(Figs. 1 and 3). In all serial passages performed in the
presence of 5-OHdC and AZT, a 90% decline in viral
infectivity was observed after the first passage. The rapid
and potent HIV-1 inhibition observed with the 5-OHdC-
AZT combination may also explain the similar frequency of
mutations found when controls and 5-OHdC-AZT-treated
cultures were compared (Table 1). The more severe
population bottleneck produced after the first passage in
the presence of the 5-OHdC-AZT combination than in the
presence of 5-OHdC alone may account for this result. This
is also supported by the higher mutation frequencies found
in the HIV-1 NL4-3 population after a single passage. One
of the possible drawbacks of the combination therapy
presented here would be the faster selection of AZT-resistant
mutants as a consequence of the mutagenic potential of 5-
OHdC. Nevertheless, the potency and rapidity of this
combination may preclude the dominance of AZT HIV-1-
resistant mutants due to he action of 5-OHdC.
Further evidence of the inhibitory capacity of the
mutagenic agent 5-OHdC has been obtained in the present
study in which the HIV-1 NL4-3 was extinguished in 2 out of
3 serial passages performed inMT4 cells in the presence of 5-
OHdC alone (Fig. 3). Similarly, the F98 HIV-1 isolate could
be extinguish in the presence of 5-OHdC after eleven
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achieved in any of the serial transfer experiments carried out
with the high fitness primary HIV-1 isolate F96 (Weber et al.,
2003) (Figs. 1 and 2). The fact that the HIV-1 NL4-3, with a
similar fitness that F96 (Weber et al., 2003), was extinguished
by treatment with 5-OHdC alone (Fig. 3) can be explained
because we transferred ten times more p24 antigen during the
F96 serial passages than in the NL4-3 transfers. This result
strongly suggests the beneficial effect of combining muta-
genic compounds with antiretrovirals to reduce the viral
replicative load and facilitate viral extinction. Furthermore,
these results are in agreement with observations on the
extinction of high-fitness FMDV isolates which was favored
by the combination of a mutagen and viral inhibitors
(Pariente et al., 2001, 2003). The molecular basis of the
sensitivity to extinction of the low fitness isolate F98, either
in the presence of 5-OHdC and AZT or in the presence of 5-
OHdC alone, remains to be elucidated. A possible explan-
ation is that the accumulation of substitutions associated with
resistance to protease and RT inhibitors may have rendered
F98 more susceptible to extinction than its wild-type
counterpart the F96 virus (Quer et al., 2001). A model
describing the association between the mutation rate of
pathogens and the degree of treatment efficacy has also
suggested that if the mutation rates of RNA viruses could be
increased (using virus-specific mutagens), antiviral treatment
efficacy could be improved (Gerrish and Garcia-Lerma,
2003). Since the maximum mutation rate tolerated by a
population increases with increasing population size (Nowak
and Schuster, 1989), the former model argues that the actions
of mutagen and antiviral(s) conveniently complement one
another to enhance treatment efficacy.
Perhaps, one of the main concerns about the use of lethal
mutagenesis as a potential antiviral approach is to find
nucleoside analogues that could increase the mutation rate of
HIV-1, with minimal toxicity to human cells. Recently, a
deoxycytidine analogue SN1212 (5,6-dihydro-5-aza-2-
deoxycytidine) showing low genotoxicity and low mito-
chondrial toxicity has been selected for clinical develop-
ment (Anderson et al., 2004). An important contribution of
the data presented here is that a combination of mutagenic
agents and antiviral drugs can increase the frequency of
viral extinction, which may allow the use of sub-toxic
concentrations of the mutagenic drug. Furthermore, drug-
resistant HIV-1 strains with impaired replication capacity
may be more susceptible to lethal mutagenesis, making
this a very attractive concept to be used in HIV-1-infected
patients on salvage therapy.Materials and methods
Serial passage experiments
Three different HIV-1 isolates were used in this study.
Two longitudinal primary HIV-1 isolates were selected froman HIV-infected individual as part of a previous study
(Cabana et al., 1999; Rangel et al., 2003; Weber et al.,
2003). Wild type F96 virus corresponded to a pre-therapy
sample, while multidrug-resistant F98 strain was obtained
2 years later after an antiviral treatment history that included
AZT, ddI, d4T, 3TC, NVP, IDV, RTV and SQV. These HIV-
1 isolates were used to study the role of viral fitness in lethal
mutagenesis. Both viruses were obtained by co-culturing the
phytohemagglutinin (PHA)-stimulated (Sigma), IL2 (Boeh-
ringer Inghelheim)-treated PBMCs from the HIV-1-infected
individual F with PBMCs from an HIV-seronegative blood
donor. When the HIV-1 p24 antigen concentration in the
culture surpassed 20 ng/ml, the supernatants were harvested.
Both viruses displayed a SI phenotype in MT-2 cells
(Rangel et al., 2003). Titration of these two viral isolates
was performed in MT-4 cells and values were expressed as
tissue culture dose for 50% infectivity (TCID50). The third
HIV-1 isolate employed here was the HIV-1 NL4-3,
obtained from the NIH AIDS Research and Reference
Reagent Program. HIV-1 NL4-3 was amplified and titrated
in MT-4 cells. Serial transfers in PBMCs were carried out as
follows. HIV-1 isolates, F96 or F98, were added at a
multiplicity of infection (MOI) of 0.01 (0.01 TCID50/cell)
to 1 ml of medium containing 7  105 PHA-stimulated, IL-
2-treated PBMCs from HIV-seronegative blood donor.
PBMCs were maintained in RPMI (Invitrogen) medium
supplemented with 20% of fetal bovine serum (Invitrogen).
Depending of the experiment, cells were previously
incubated for 1 h with 2 mM of 5-OHdC (Berry Associates,
MI), 0.01 AM of AZT (Sigma) or both. After 7 days (one
passage), the amount of supernatant containing 6000 pg of
p24 antigen was transferred to fresh PBMCs that were
preincubated with or without 5-OHdC or AZT or both for
1 h. This procedure was iterated for 5 cycles (5 weeks) (Fig.
1) or 16 cycles (16 weeks) (Fig. 2). Aliquots of both cells
and supernatants were frozen at each passage. Virus
production was monitored by measuring HIV p24 antigen
in culture supernatants with the Innogenetics ELISA kit.
MT-4 serial passages were performed by infecting 2  105
cells with the HIV-1 NL4-3 at the MOI of 0.01 (0.01
TCID50/cell). After 6–7 days (one passage), the amount of
supernatant containing 500 pg of p24 antigen was trans-
ferred to fresh cells. This procedure was iterated for
13 cycles (13 weeks) (Fig. 3). The effect of 5-OHdC on
PBMC’s viability was monitored by trypan blue exclusion
after incubating the cells with different amounts of the
mutagenic agent during 7 days. The toxicity (CC50) of 5-
OHdC for MT-4 cells was quantified by determining the
number of viable cells using a tetrazolium-based colori-
metric assay (MTT method) as described elsewhere
(Pauwels et al., 1988). The CC50 of 5-OHdC was > 2
mM. To assess the 50% inhibitory concentration (IC50) of
5-OHdC, HIV-infected MT4 cells were exposed to increas-
ing concentrations of the compound as previously described
(Martinez et al., 2000). The IC50 calculated for 5-OHdC
was >2 mM.
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complexity
Genomic DNA from 7  105 PBMCs or 2  105 MT-4
cells was purified using the QIAamp DNA Blood Kit
(QIAGEN). Proviral DNA was amplified by nested PCR.
The HIV-1 protease gene was amplified from 5 Al of
resuspended DNA by use of the following published
(Ibanez et al., 2000; Parera et al., 2004) oligonucleotides:
5Vprot 1 and 3Vprot 1, for the first PCR, and 5Vprot 2 and
3Vprot 2, for the nested PCR. PCR conditions have also been
published elsewhere (Ibanez et al., 2000). The amplified
DNA was cloned into the pGEM-T Easy Vector System I
(Promega). The DNA inserts were sequenced by using the
flanking oligonucleotides sp6 and T7. The amount of input
proviral DNA for the first step of the nested PCR was
determined by PCR amplification of serial dilutions of the
proviral DNA. An input proviral DNA copy number of 500
times the end point for positive PCR amplification was used
to ensure that multiple proviral HIV-1 templates were
present in each sample. Since we used uncloned virus as
our starting inoculum in the serial viral transfers, mutations
present in more than one of the control clones were
excluded from our analysis.Acknowledgments
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